VA
APGE

Vident Advisory’s Apogee Therapeutics APGE Stock Holding History

Vident Advisory’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Sell
3,148
-237
-7% -$21.4K ﹤0.01% 1455
2026
Q1 		$285K Buy
3,385
+494
+17% +$35.9K ﹤0.01% 1526
2025
Q4 		$218K Buy
+2,891
New +$182K ﹤0.01% 1521

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Vident Advisory's APGE Position: Q2 2026 in Review

Vident Advisory reduced its Apogee Therapeutics (APGE) stake by 7% in Q2 2026, selling an estimated $21.4K and leaving 3,148 shares worth $418K. The position accounts for ﹤0.01% of the portfolio, ranked #1455.

Vident Advisory first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Vident Advisory held 3,148 shares of Apogee Therapeutics worth $418K as of Q2 2026.
  • Vident Advisory sold 237 Apogee Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Apogee Therapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1455 holding.
  • Vident Advisory first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.